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BACKGROUND & AIMS: Simeprevir is an oral, once-daily in-
hibitor of hepatitis c virus (HCV) protease NS3/4A. We inves-
tigated the safety and efﬁcacy of simeprevir with peg-interferon
a-2a and ribavirin (PR) in a randomized, double-blind, placebo-
controlled, phase 3 trial of patients with HCV genotype 1
infection who relapsed after previous interferon-based therapy.
METHODS: Patients were assigned randomly (2:1) to groups
given simeprevir (150 mg, once daily) and PR (n ¼ 260) or
placebo and PR (n ¼ 133) for 12 weeks. Patients then were
given PR alone for 12 or 36 weeks (simeprevir group, based on
response-guided therapy criteria) or 36 weeks (placebo group).
RESULTS: Simeprevir and PR was signiﬁcantly superior to placebo
andPR; rates of sustained virologic response 12weeks after planned
endof treatment (SVR12)were79.2%vs36.1%, respectively (43.8%
difference; 95% conﬁdence interval, 34.6–53.0; P < .001). Among
patients given simeprevir, 92.7% met the response-guided therapy
criteria andwere eligible to complete PR atweek 24; of these, 83.0%
achieved SVR12. HCV RNA was undetectable at week 4 in 77.2% of
patients given simeprevir and 3.1% given placebo. On-treatment
failure and relapse rates were lower among patients given sime-
previr and PR than those given placebo and PR (3.1% vs 27.1%, and
18.5% vs 48.4%, respectively). Patients given simeprevir did not
have adverse events beyond those that occurred in patients given PR
alone. Most adverse events were grades 1/2; the prevalence of ane-
mia and rash was similar in both groups. Patients in both groups
reported similar severity of fatigue and functional impairments
during the study, but duration was reduced among patients given
simeprevir. CONCLUSIONS: In a phase 3 trial of patients who had
relapsed after interferon-based therapy, the addition of simeprevir
to PR was generally well tolerated, with an SVR12 rate of 79.2%.
Most patients (92.7%) receiving simeprevir were able to shorten
therapy to 24 weeks. ClinicalTrials.gov number: NCT01281839.Keywords: PROMISE; Chronic Hepatitis C; Drug; DAA.
pproximately 150 million individuals worldwideAare chronically infected with hepatitis C virus (HCV),
with 350,000 people dying annually of HCV-related condi-
tions.1 Historically, the standard of care for chronic HCV
infection was peginterferon (PegIFN)a and ribavirin (RBV).2–4
However, 50%–60% of HCV genotype 1–infected patients do
not achieve sustained virologic response (SVR) with PegIFNa/
RBV,5,6 and up to 32% of responders relapse after cessation of
therapy.7 Re-treatment of relapsed patients with PegIFNa/
RBV has SVR rates of approximately 20%–50%.8–10
The direct-acting antiviral agents (DAAs), boceprevir and
telaprevir, can improve SVR rates when dosed with
PegIFNa/RBV,11–14 with the potential for a shorter treat-
ment duration in some patients.11,13,15 The telaprevir 50%
inhibitory concentration (IC50) values in a genotype 1b HCV
replicon and in genotype 1a HCV-infected human fetal he-
patocytes were 354 nmol/L and 280 nmol/L, respectively,16
whereas the boceprevir median effective concentration
(EC50) in a genotype 1b HCV replicon was approximately
200 nmol/L, with an approximately 2-fold lower value in a
genotype 1a HCV replicon.17 Data concerning the efﬁcacy of
response-guided treatment (RGT) with telaprevir in patients
who have relapsed after prior IFN-based therapy are
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daily, whereas telaprevir must be administered 2 or 3 times
daily (6 pills in total).18 Boceprevir and telaprevir also are
associated with a high incidence of adverse events (AEs),
including anemia, rash, and renal dysfunction.19–22 Recently,
the nucleotide analog NS5B polymerase inhibitor sofosbuvir
also was approved for the treatment of chronic HCV infec-
tion in the United States and Europe, representing an
improvement on ﬁrst-generation DAAs.23,24
Simeprevir (TMC435) is administered orally, once daily,
as a single pill25; has been approved in Japan, Canada, the
United States and Russia; and is under regulatory review in
Europe for the treatment of chronic HCV infection. The
median simeprevir EC50 and EC90 values against a HCV
genotype 1b replicon were 9.4 and 19 nmol/L, respec-
tively.26 Activity of simeprevir against a selection of geno-
type 1a (N ¼ 78) and 1b (N ¼ 59) chimeric replicons
carrying NS3 sequences from HCV NS3/4A protease
inhibitor-naive subjects resulted in median fold change in
EC50 of 1.4 (interquartile range [IQR], 0.8–11) and 0.4 (IQR,
0.3–0.7), compared with reference genotype 1b replicon.
Genotype 1a (N ¼ 33) and 1b (N ¼ 2) isolates with a
baseline Q80K polymorphism, a naturally occurring NS3
polymorphism that confers low-level resistance to sime-
previr, resulted in a median fold change in simeprevir EC50
of 11 (IQR, 7.4–13) and 8.4, respectively.
Simeprevir has antiviral activity in patients infected with
HCV genotypes 1, 2, 4, 5, and 6,27–30 and is being evaluated
in both PegIFNa/RBV and IFN-free combinations.27,28,31–34
Simeprevir in combination with PegIFNa/RBV showed
SVR rates of approximately 80% in phase 3 trials in
treatment-naive patients with HCV genotype 1 infection,
with most patients (>84%) able to reduce their treatment
duration to 24 weeks.33,34 In these studies, no additional
AEs were observed with simeprevir compared with those
seen with PegIFNa/RBV alone.
Results of the PROtease inhibitor TMC435 In patientS
who have previously rElapsed on IFN/RBV (PROMISE) study,
a randomized, double-blind, placebo-controlled, phase 3 trial
undertaken to assess the efﬁcacy, safety, and tolerability
of simeprevir with PegIFNa-2a/RBV (PR) for the treatment of
chronic HCV genotype 1 infection in patients who had
relapsed after previous IFN-based therapy, are presented.Materials and Methods
Patients
Patients were enrolled at study sites in 14 countries across
North America, Europe, and the Asia–Paciﬁc region. Eligible
patients were adults (18 y) with conﬁrmed genotype 1 HCV
infection and screening plasma HCV-RNA levels greater than
10,000 IU/mL, who had relapsed after 24 weeks or more of
IFN-based therapy (undetectable HCV-RNA at end of treatment
[EOT] or within 2 months after EOT, with documented relapse
within 1 year after therapy). A liver biopsy specimen obtained
within 3 years of screening showing histology consistent with
chronic HCV infection was required, according to the 2010
Food and Drug Administration (FDA) Guidance for Industry on
developing DAAs (available from the FDA). Biopsy specimensindicating a METAVIR score of F0–F3 within 3 years of
screening, or a score of F4 at any previous time, were accept-
able. In total, 68% of patients had a biopsy within a year of
screening. Subjects with bridging ﬁbrosis (F3) or cirrhosis (F4)
were eligible if they had an ultrasound performed within 6
months before screening (or between the screening and base-
line visit) with no ﬁndings suspicious for hepatocellular carci-
noma. Patients with hepatic decompensation; non–HCV-related
liver disease; co-infection with human immunodeﬁciency virus,
hepatitis B virus, or non–genotype 1 HCV; deﬁned laboratory
abnormalities (Supplementary Materials and Methods section);
any other active disease; or who were either pregnant or
planning pregnancy were excluded.
Study Design
This was a randomized, multicenter, double-blind, parallel-
group, placebo-controlled, phase 3 clinical trial
(NCT01281839), conducted between January 2011 and January
2013. Institutional review boards of all participating in-
stitutions approved the study and written informed consent
was obtained from all participants according to local regula-
tions. All authors had access to the study data, critically
reviewed the manuscript at each draft, and approved the ﬁnal
draft for submission.
After stratiﬁcation by HCV 1 subtype (1a, 1b, and other) and
IL28B genotype (rs12979860; CC, CT, or TT), participants were
randomized centrally in a 2:1 ratio to receive either simeprevir
(150 mg once daily) plus PegIFNa-2a/RBV (180 mg/wk and 1000
or 1200 mg/day depending on body weight, respectively) (PR)
for 12 weeks followed by RGT with PR alone for 12 or 36 weeks,
or placebo with PR for 12 weeks followed by PR alone for 36
weeks (Supplementary Figure 1). Patients, study personnel, and
the sponsor were blinded to the treatment groups. According to
RGT criteria, PR therapy was completed at week 24 in
simeprevir-treated patients with HCV-RNA levels less than 25 IU/
mL at week 4 and undetectable levels at week 12. For patients
not meeting these criteria and all patients in the placebo group,
treatment with PR was continued until week 48. Patients in both
groups were followed-up for 72 weeks after treatment initiation.
According to virologic stopping rules, simeprevir/placebo
was discontinued if HCV-RNA level was greater than 1000
IU/mL at week 4. PR also was discontinued if the reduction in
HCV RNA compared with baseline was less than 2 log10 IU/mL
at week 12, or if HCV RNA was 25 IU/mL or greater at week 24
or 36. Investigators were formally blinded to HCV-RNA data
until week 48 and to treatment group until week 72. An
external HCV-RNA monitor (who was unblinded to treatment
and to HCV-RNA measurements results) informed the investi-
gator if a virologic stopping rule or the RGT criteria were met.
Assessments
Plasma HCV RNA was determined using the Roche COBAS
TaqMan HCV/HPS assay version 2.0 (Roche Molecular Di-
agnostics, Pleasanton, CA). Standard population-based
sequencing of the HCV NS3/4A protease domain was per-
formed on baseline samples to determine the presence of natu-
rally occurring baseline polymorphisms, including Q80K, and
those from selected time points (based on HCV-RNA changes).
Standard HCV genotyping assays, the Siemens Versant HCV
LiPA v2 assay (Siemens Healthcare Diagnostics, Tarrytown, NY)
or, if that failed, the Trugene 50NC genotyping assay, were used
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HCV genotype/subtype was determined at baseline using an
NS5B sequence-based assay. The results of the NS5B-based
assay were used for study analyses. Determination of the pa-
tients’ IL28B genotype (SNP rs12979860) was performed on
human genomic DNA by a real-time polymerase chain reaction
on the ABI 7900HT platform.
AEs were monitored throughout the study. During study
visits, patients completed questionnaires to document changes
in fatigue severity (Fatigue Severity Scale),35 as well as pro-
ductivity and daily activity impairment and work absenteeism
(Work Productivity and Activity Impairment questionnaire for
Hepatitis C).36
Additional details are provided in the Supplementary
Materials and Methods section.
Statistical Analysis
This primary analysis was performed when all randomized
and treated subjects had completed the week 60 visit or dis-
continued earlier. All analyses were performed on the intent-to-
treat population, which comprised all subjects who received at
least one dose of simeprevir or placebo. The primary study end
point was the proportion of patients achieving SVR (HCV RNA
<25 IU/mLundetectable at actual EOT andHCVRNA<25 IU/mL)
12 weeks after planned EOT (SVR12). SVR12 rates in the
2 groups were compared using the Cochran–Mantel–Haenszel
test controlling for stratiﬁcation factors (HCV 1 subtype and
IL28B genotype). A Breslow–Day test for homogeneity of odds
ratios based on this model also was performed and the 95%
conﬁdence interval (CI) was constructed around each response
rate. Phase 3 data for telaprevir and boceprevir show a strong
correlation between SVR12 and SVR at 24 weeks after planned
EOT (SVR24). Similarly, a good correlation also was observed in
phase 2b studies with simeprevir. Sample size calculation based
on SVR24 rates therefore was regarded as applicable for SVR12.
Based on published data,37 the SVR24 rate in the placebo group
was expected to be approximately 20%. It was calculated that
250 patients in the simeprevir group and 125 patients in the
placebo group were needed to provide more than 90% power to
detect a signiﬁcant difference between the 2 treatment groups
with a 5% signiﬁcance level (2-sided).
Secondary end points included comparison of virologic
response rates at other time points (SVR24 [data are presented
in the Supplementary Results section] and rapid virologic
response [RVR] rate, deﬁned as the proportion of patients with
undetectable HCV RNA at week 4 of treatment) and in different
patient subgroups (including METAVIR score, HCV 1 subtype,
and IL28B genotype), the proportion of simeprevir-treated
patients meeting RGT criteria to complete treatment at week
24, the incidence of viral breakthrough (HCV-RNA increase of
>1 log10 IU/mL from the lowest level observed or HCV RNA
>100 IU/mL when previously <25 IU/mL), on-treatment failure
(conﬁrmed detectable HCV RNA at EOT), or viral relapse
(presence of detectable HCV RNA during follow-up or at the
time of SVR assessments after achieving undetectable levels at
EOT), the incidence of AEs and laboratory abnormalities, and
quality-of-life measures. The 95% CIs were constructed around
the observed response rates and for the differences in response
rates between treatment groups.
Patient-reported fatigue and impairment in productivity,
daily activities, and missed work time were analyzed as changefrom baseline using a piecewise linear model comparing the
area under the score–time curve from baseline with week 60,
allowing slopes to change over time for each treatment arm.
These end points were prespeciﬁed in the statistical analysis
plan in the order presented as part of a closed testing proce-
dure to address multiple testing of secondary end points. All
statistical analyses were performed using SAS version 9.1 (SAS
Institute, Inc, Cary, NC).Results
Patients
A total of 462 patients were screened; of these, 394 were
randomized and 393 were treated (260 in the simeprevir/
PR group and 133 in the placebo/PR group) (Supplementary
Figure 2). At the time of this primary analysis, all patients had
reached the time point at which the primary end point
(SVR12) was assessed (ie, week 60), or had discontinued
earlier. In addition, 184 patients (46.8%) had completed the
ﬁnal week 72 visit, and 24 (6.1%) had discontinued the study
prematurely. The main reasons for study discontinuation
were withdrawal of consent (14 patients; 3.6%) and loss to
follow-up evaluation (8 patients; 2.0%).
Most (93.1%) patients in the simeprevir/PR group
completed their assigned treatment regimen (compared
with 25.6% in the placebo/PR group). The proportion of
patients who discontinued simeprevir/placebo intake early
was 3.5% and 72.2% in the simeprevir/PR and placebo/PR
groups, respectively. The main reason for discontinuation
was meeting the week 4 virologic stopping rule for sime-
previr or placebo in both arms, with a large proportion of
patients in the placebo group (69.9%) stopping placebo at
week 4. The proportion of patients who completed PR
treatment was 93.5% in the simeprevir/PR group (24 or 48
weeks) and 72.2% in the placebo/PR group (48 weeks).
Baseline demographic and disease characteristics were
comparable between groups (Table 1; Supplementary
Results section). The median times (in months) between
the end of previous (Peg)IFN-based therapy and the start of
treatment in this study were as follows: 31.0 (4; 141) and
31.0 (5; 115) for the simeprevir and placebo groups.Efﬁcacy
In the simeprevir/PR arm, an SVR12 rate of 79.2% (206
of 260) was observed compared with 36.1% (48 of 133)
with placebo/PR (Table 2, Figure 1A). The difference be-
tween the 2 groups (controlling for HCV 1 subtype and
IL28B genotype as stratiﬁcation factors) was statistically
signiﬁcant at 43.8% (95% CI, 34.6–53.0; P < .001).
The majority of simeprevir-treated patients (92.7%; 241
of 260) met RGT criteria to complete treatment at week 24,
of whom 83.0% (200 of 241) achieved SVR12. Among
simeprevir-treated patients who did not meet RGT criteria,
40.0% (6 of 15) achieved SVR12.
The RVR rate was 77.2% (200 of 259) in the simeprevir/
PR group compared with 3.1% (4 of 129) treated with
placebo/PR. Among simeprevir-treated patients who ach-
ieved RVR, 86.5% (173 of 200) subsequently achieved
Table 1.Baseline Demographics and Disease Characteristics
Simeprevir 150 mg
12 weeks þ PR
(n ¼ 260)
Placebo þ PR
(n ¼ 133)
Sex, %
Male 68.8 59.4
Female 31.2 40.6
Race, %
White 93.5 96.2
Black/African American 2.7 3.0
Native Hawaiian or Other Paciﬁc Islander 0.4 0.0
Asian 3.1 0.8
Multiple 0.4 0
Ethnicity, %
Hispanic or Latino 7.7 4.5
Median age, y (range) 52.0 (20–70) 52.0 (21–71)
Median body mass index (range) 27.2 (14.3–47.7) 26.8 (18.5–41.6)
IL28B genotype, %
TT 11.9 12.0
CT 64.2 62.4
CC 23.8 25.6
METAVIR ﬁbrosis score, %a
F0–F1 34.8 35.6
F2 32.0 38.6
F3 17.6 11.4
F4 15.6 14.4
Median baseline HCV RNA, log10 IU/mL (range) 6.42 (4.6–7.7) 6.54 (3.1–7.5)
HCV genotype, %
1 0.4 0
1a 42.3 40.6
1b 57.3 59.4
Previous HCV therapy, %
PegIFNa-2a/RBV 68.5 66.2
PegIFNa-2b/RBV 26.9 27.1
Other 4.6 6.8
FSS score
N 250 131
Mean score (SE) 3.6 (0.10) 3.3 (0.12)
WPAI productivity
N 246 129
Mean score (SE) 19.0 (1.53) 15.6 (1.88)
WPAI daily activity impairment
N 246 129
Mean score (SE) 19.4 (1.55) 15.4 (1.84)
WPAI absenteeism
N 129 60
Mean (SE) 1.2 (0.60) 5.8 (2.60)
FSS, Fatigue Severity Scale; WPAI, work productivity and activity impairment: hepatitis C questionnaire.
aLiver biopsy obtained within 3 years of screening (or between the screening and baseline visit) with histology consistent with
chronic HCV infection.
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patients had HCV-RNA level of 25 IU/mL or greater.
Irrespective of factors such as baseline HCV-RNA level,
IL28B genotype, METAVIR score, and HCV subtype, SVR12
rates were signiﬁcantly higher in the simeprevir/PR group
than in the placebo/PR group (all P < .001) (Table 3,
Figure 1B). In simeprevir-treated patients with HCV geno-
type 1a infection, the presence of the Q80K polymorphism
at baseline was associated with a lower SVR12 rate
compared with those without this polymorphism at baseline(46.7% [14 of 30] vs 78.5% [62 of 79], respectively).
However, the SVR12 rate was high among the 13
simeprevir-treated patients with baseline Q80K poly-
morphism who achieved RVR (76.9% vs 23.5% among pa-
tients without RVR). Only one simeprevir-treated patient
with HCV genotype 1b infection had Q80K polymorphism at
baseline; this patient achieved SVR12. The possible effect of
baseline characteristics and early response parameters on
SVR12 in the simeprevir/PR group is presented in
Supplementary Table 1.
Table 2.Virologic Response Over Time (RVR and SVR12), Proportion of Patients Meeting RGT Criteria and Corresponding
SVR12 Rate, and Rates of On-Treatment Failure and Relapse
Simeprevir 150 mg þ PR
(n ¼ 260)
Placebo þ PR
(n ¼ 133)
RVR 200/259 (77.2) 4/129 (3.1)
SVR12 206/260 (79.2) 48/133 (36.1)
Met RGT criteria 241/260 (92.7) N/A
SVR12 in patients who met RGT criteria 200/241 (83.0) N/A
SVR12 in patients who did not meet RGT criteria 6/15 (40.0) N/A
On-treatment failurea 8 (3.1) 36 (27.1)
Virologic stopping rule met at weeks 12, 24, or 36 5 (1.9) 15 (11.3)
Viral relapseb 46/249 (18.5) 45/93 (48.4)
NOTE. All differences between the simeprevir and placebo groups: P < . 001. SVR12 was deﬁned as HCV RNA <25 IU/mL
undetectable at the actual EOT and HCV RNA <25 IU/mL 12 weeks after the planned end of treatment.
N/A, not applicable.
aConﬁrmed detectable HCV-RNA levels at actual EOT.
bAmong patients with undetectable HCV-RNA levels at actual EOT.
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simeprevir/PR and 27.1% (36 of 133) for placebo/PR
(Table 2). Five patients (1.9%) in the simeprevir/PR group
and 93 patients (69.9%) in the placebo/PR group met the
virologic stopping rule at week 4, which dictated stopping
simeprevir/placebo only and continuing with PR. Respective
proportions of patients meeting a virologic stopping rule
requiring discontinuation of all treatment at weeks 12, 24,
or 36 were 1.9% (5 of 260) and 11.4% (15 of 133) in the
simeprevir/PR and placebo/PR groups. Viral breakthrough
occurred in 2.3% (6 of 260) of simeprevir-treated patients;
this rate was similar in patients infected with genotype
1a/other (2.7%) and genotype 1b (2.0%). No placebo-
treated patients had viral breakthrough. Viral break-
through occurred mainly during the ﬁrst 12 weeks of
treatment with simeprevir/PR, and 5 of 6 simeprevir-
treated patients with viral breakthrough also met a viro-
logic stopping rule. Among patients with undetectable HCV
RNA at EOT, 18.5% (46 of 249) in the simeprevir/PR group
and 48.4% (45 of 93) in the placebo/PR group had expe-
rienced viral relapse. With simeprevir, this occurred less
frequently in patients infected with genotype 1b (17 of 144;
11.8%) than in those with genotype 1a/other (29 of 105; 27.6%).
NS3 sequencing data were available for 52 of the
59 simeprevir-treated patients who did not achieve SVR12
(n ¼ 54) or who relapsed after the SVR12 time point
(n ¼ 5). Most of these patients (considering NS3 positions
43, 80, 122, 155, 156, and 168) had emerging mutations in
the NS3 protease domain at the time of failure (90.4%). In
genotype 1a–infected patients, this was mainly R155K alone
or with other amino acid substitutions at positions 80 or
168. For genotype 1b, this was mainly D168V or other
mutations at position 168 (Table 4).Safety and Tolerability
During the ﬁrst 12 weeks of treatment, the most
frequent AEs in the simeprevir/PR group (>25% of pa-
tients) were headache, fatigue, and inﬂuenza-like illness(Table 5). AEs were mainly grades 1/2. Grades 3/4 AEs
were reported in 20.0% of patients in the simeprevir/PR
group and in 21.1% in the placebo/PR group, with serious
AEs (SAEs) reported in 1.2% and 2.3% of patients, respec-
tively. Grades 2/3 photosensitivity reaction was reported as
an SAE in 2 simeprevir-treated patients (0.8%). No other
SAE was reported in more than 1 patient in either group. No
patient discontinued simeprevir or placebo alone owing to
AEs. During the ﬁrst 12 weeks of treatment, AEs led to
permanent discontinuation of all study drugs in 0.4% of
simeprevir-treated and no placebo-treated patients. The
same discontinuation rates were reported during the entire
treatment phase for each of the treatment groups.
Two deaths have been reported, both after the ﬁrst 12
weeks of treatment (Table 5). One patient in the simepre-
vir/PR group (METAVIR score F4 at baseline) died 5 days
after consent withdrawal owing to SAEs considered unre-
lated to simeprevir by the investigator (pancytopenia,
bradycardia, pyrexia, pneumonia, septic shock, confusional
state, dyspnea, and respiratory acidosis). One patient in the
placebo group also died of an SAE considered unrelated to
treatment (primary liver cancer with lung metastasis).
Isolated mild and reversible increases in bilirubin
(direct, indirect, and total) were observed in the sime-
previr/PR group during the ﬁrst 2 weeks of treatment, but
were not accompanied by changes in any other liver pa-
rameters. During the ﬁrst 12 weeks of treatment,
increased bilirubin AEs (mainly grades 1/2) were re-
ported in 5.8% of simeprevir-treated and in 2.3% of
placebo-treated patients. Grades 3 or 4 increased bilirubin
AEs occurred in 1.5% and 0.4% of simeprevir-treated
patients, respectively, but none led to discontinuation of
simeprevir. Grades 3/4 hyperbilirubinemia (laboratory
reported) occurred in 6.2% of simeprevir-treated and in
3.1% of placebo-treated patients.
Rash, pruritus, neutropenia, and anemia AEs were
comparable between the simeprevir and placebo groups
(Table 5). For rash and pruritus, all AEs were grades 1/2,
except for 1 case of grade 3 rash in the simeprevir group
Figure 1. (A) SVR12 rates.
(B) Differences in SVR12
by patient subgroup. Dif-
ferences in the proportions
and their respective CIs
are derived from a logistic
regression model including
factors for treatment
group, baseline HCV RNA
(log10 IU/mL), HCV 1 sub-
type, and IL28B.
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possibly related to simeprevir), and did not lead to treat-
ment discontinuation. Photosensitivity AEs were reported in
3.5% of simeprevir-treated and in no placebo-treated pa-
tients. With the exception of the case of grade 3 photosen-
sitivity in the simeprevir group, these were grades 1/2 and
did not lead to treatment discontinuation. Most anemia AEs
were grades 1/2 and did not lead to treatment discontinu-
ation, with grade 3 anemia occurring in 1.2% of simeprevir-
treated and in 2.3% of placebo-treated patients. No cases of
grade 4 anemia were reported.In terms of laboratory abnormalities, decreases in he-
moglobin were observed in 16.5% of simeprevir-treated
and in 13.0% of placebo-treated patients. These were of
grade 3 severity in 0.8% of simeprevir-treated and in 1.5%
of placebo-treated patients, with no grade 4 decreases in
hemoglobin in either group. No differences were observed
for any other laboratory abnormalities between the 2
groups. The only grades 3/4 laboratory abnormality
observed in more than 10% of simeprevir-treated patients
was a decrease in absolute neutrophil count (14.6% with
simeprevir and 17.6% with placebo).
Table 3.SVR12 Rates According to IL28B Genotype, METAVIR Score, and HCV Genotype
Simeprevir 150 mg þ PR
(n ¼ 260)
Placebo þ PR
(n ¼ 133)
Difference between groups
(simeprevir–placebo, 95% CI)a
IL28B genotype, %
TT 20/31 (64.5) 3/16 (18.8) 40.0 (27.4–52.7)
CT 131/167 (78.4) 28/83 (33.7) 49.1 (38.9–59.4)
CC 55/62 (88.7) 18/34 (52.9) 31.0 (18.9–43.1)
METAVIR ﬁbrosis score, %
F0–F2 137/167 (82.0) 40/98 (40.8) 49.9 (39.6–60.3)
F3–F4 61/83 (73.5) 8/34 (23.5) 51.4 (41.5–61.3)
F3 32/44 (72.7) 3/15 (20.0) 51.3 (41.4–61.1)
F4 29/39 (74.4) 5/19 (26.3) 51.6 (41.5–61.6)
HCV genotype, %
1a/other 78/111 (70.3) 15/54 (27.8) 49.2 (34.8–63.7)
With baseline Q80K 14/30 (46.7) 6/20 (30.0%) 18.6 (-7.5 to 44.7)
Without baseline Q80K 62/79 (78.5) 9/34 (26.5%) 60.1 (43.9–76.3)
1b 128/149 (85.9) 34/79 (43.0) 44.9 (31.6–58.2)
aThe difference in proportions and respective 95% CIs are derived from a logistic regression model.
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RMean scores for patient-reported fatigue, productivity
impairment, and impairment in daily activities increased by
similar amounts from baseline to week 4 in the 2 treatment
groups, and remained increased through week 24 in bothTable 4.Emerging Mutations at Time of Failure in Patients Not
Proportion of patients with
emerging mutations among
patients not achieving SVR
Eme
fai
Overall 47/52 (90.4)
GT1aa with Q80K 12/14 (85.7) 8/12
3/12
1/12
GT1a without Q80K 18/18 (100) 7/18
4/18
w
p
7/18
GT1b 17/20 (85.0) 8/17
7/17
2/17
NOTE.Data shown take into considerationNS3positions43, 80, 1
of these positions are either known to confer reduced susceptibili
experiments. Considering a longer list of 18NS3 amino acid positi
with resistance to other HCV NS3/4A protease inhibitors or that w
in vitro or in vivo studies (18NS3aminoacidpositionsof interest: 3
170, 174, and 175), 4 patients had additional mutations: 1 HCV ge
mutation I170T. I170T also was observed in another HCV gen
emerging R155K. One HCV genotype 1b patient had emerging V
nation with D168V. Similar mutations were observed at other tim
beyond the 18 positions of interest in the NS3 protease domain
than 1 patient and always in combination with emerging muta
GT1a, HCV genotype 1a; GT1b, HCV genotype 1b.
aGenotype 1a might include a few patients with non-1a/1b HCVgroups. Fatigue, productivity impairment, and activity
impairment improved to levels at or below baseline in the
simeprevir/PR group after week 24, when most simeprevir-
treated patients were able to complete therapy owing toAchieving SVR
rging mutations at time of
lure (overview), n/N (%)
Emerging mutations at
time of failure
(66.7) R155K
(25.0) D168E
(8.3) S122R S122R (n ¼ 1)
(38.9) R155K
(22.2) R155K in combination
ith mutations at NS3
ositions 80 or 168
R155KþD168E (n ¼ 1),
R155KþD168A (n ¼ 1,
Q80Kþ R155K (n ¼ 2)
(38.9) D168V, A, A/V, E or H D168V (n ¼ 2), D168A (n ¼ 2),
D168A/V (n ¼ 1),
D168E (n ¼ 1), D168H (n ¼ 1)
(47.1) D168V
(41.2) D168A, E, T or E/V D168A (n ¼ 3), D168E or E/V
(n ¼ 3), D168T (n ¼ 1)
(11.8) Other Q80RþD168E/V(n ¼ 1),
Q80RþS122TþD168E (n ¼ 1)
22, 155, 156, and168.Speciﬁcaminoacid changesat 1ormore
ty to simeprevir in vitro or have emerged during in vitro selection
ons that also includesNS3positions that have been associated
ere considered of interest based on observations in simeprevir
6, 41, 43, 54, 55, 80, 107, 122, 132, 138, 155, 156, 158, 168, 169,
notype 1a patient with Q80K at baseline had a single emerging
otype 1a patient without baseline Q80K in combination with
107I in combination with D168V and another S174F in combi-
e points in patients not achieving SVR. Emerging mutations
were infrequent, the same mutation was observed in no more
tions at positions 80, 155, and/or 168.
genotype.
Table 5.Adverse Events During the First 12 Weeks of Treatment (Simeprevir/Placebo Plus PR Treatment Phase)
Patients, % Patients, %
Simeprevir 150 mg
12 weeks þ PR
(n ¼ 260)
Placebo þ PR
(n ¼ 133)
Simeprevir 150 mg
12 weeks þ PR
(n ¼ 260)
Placebo þ
PR
(n ¼ 133)
First 12 weeks Entire treatment phase
Any AE 95.4 92.5 97.3 94.0
Grade 1 or 2 AE 75.4 71.4 69.6 63.9
Grade 3 AE 18.1 18.0 24.2 25.6
Grade 4 AE 1.9 3.0 3.5 4.5
AE with fatal outcome 0 0 1 1
SAE 1.2 2.3 5.4 7.5
AE leading to permanent
discontinuation of:
At least 1 study drug 1.2 1.5 2.3 5.3
Simeprevir/placebo and PR 0.4 0 0.4 0
Simeprevir/placebo only 0 0 0 0
PegIFNa-2a and/or RBV 0.8 1.5 1.9 5.3
PegIFNa-2a only 0 0 0 0
RBV only 0 0 0 0.8
Most common AEsa
Fatigue 31.9 42.1 32.3 43.6
Headache 31.9 36.1 33.1 36.1
Inﬂuenza-like illness 29.6 20.3 30.0 20.3
AEs of clinical interest
Rash 18.5 14.3 23.1 22.6
Pruritus 23.5 16.5 27.7 27.8
Neutropenia 14.6 16.5 17.7 21.8
Photosensitivity 3.5 0 3.5 0
Anemia 10.8 6.0 16.9 20.3
aAEs occurring in more than 25% of patients in the simeprevir group in the ﬁrst 12 weeks and during the entire treatment
phase.
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48 in the placebo/PR group (Figure 2A–C). As a result,
signiﬁcantly lower fatigue, productivity impairment, and
activity impairment was observed in simeprevir-treated
compared with placebo-treated patients over the entire
study period (P < .001). Similar trends were not observed
for patient-reported time missed from work. Absenteeism
scores for the subset of patients in the labor force at
baseline showed no signiﬁcant difference between groups
(P ¼ .701; Figure 2D).Discussion
This study was performed to assess the efﬁcacy and
safety of simeprevir in combination with PR in patients with
chronic HCV genotype 1 infection who had relapsed after
previous IFN-based therapy. Oral, once-daily treatment with
simeprevir 150 mg for 12 weeks in combination with PR
followed by treatment for 12–36 weeks with PR was asso-
ciated with a signiﬁcant improvement in SVR12 in this pa-
tient population compared with that seen in the placebo
control group. SVR in this study was deﬁned as HCV RNA
less than 25 IU/mL undetectable at actual EOT and less than25 IU/mL detectable/undetectable 12 weeks after planned
EOT; all simeprevir-treated patients who achieved SVR12
had undetectable levels at the SVR12 time point. Overall,
79.2% of simeprevir-treated patients achieved SVR12
compared with 36.1% of those who received PR alone. In
this study, an RGT strategy was used to allow individualized
shortening of PR treatment duration to 24 weeks based on
early virologic response. A shorter overall treatment dura-
tion is highly desirable in patients with chronic HCV infec-
tion because it reduces exposure to PR, resulting in reduced
costs and a lower incidence of treatment-related AEs.38–40
Almost all simeprevir-treated patients (92.7%) met RGT
criteria and were eligible to stop PR at week 24. The SVR12
rate in these patients was 83.0%, supporting this treatment
approach. Among the 77.2% of simeprevir-treated patients
with RVR (HCV RNA <25 IU/mL undetectable at week 4),
86.5% achieved SVR12. As expected, the relapse rate in
patients treated with simeprevir/PR was lower than in
those who received PR alone (18.5% compared with
48.4%).
In this study, more than 30% of patients had bridging
ﬁbrosis or cirrhosis (given that a 3-year biopsy window was
allowed, the proportion of patients with cirrhosis may have
Figure 2. Change in score
from baseline in (A) patient-
reported fatigue, (B) pro-
ductivity impairment, (C)
activity impairment, and (D)
absenteeism.
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Rbeen underestimated; however, this approach was based on
FDA guidance that was current at the time of patient
enrolment in this trial). In patients with baseline METAVIR
F3–F4 scores, SVR12 rates were signiﬁcantly higher in those
treated with simeprevir/PR than in those who received
placebo/PR (73.5% vs 23.5%, respectively; P <.001). The
SVR12 rates in simeprevir-treated patients were also higher
than in those who received placebo/PR across IL28B geno-
types (88.7% vs 52.9% for CC, 78.4% vs 33.7% for CT, and
64.5% vs 18.8% for TT; all P < .001). The SVR12 rates with
simeprevir were lower in HCV genotype 1a patients who
had the Q80K polymorphism at baseline compared with
those without this polymorphism (46.7% vs 78.5%). The
impact of the Q80K polymorphism on SVR varied depending
on the presence of baseline characteristics associated with
poor treatment outcome. As seen with patients with Q80K,
the SVR rates differed based on week 4 virologic response.
For example, among simeprevir-treated patients harboring
Q80K who had RVR (13 of 29), most achieved SVR12
(76.9%). Although the Q80K variant itself only has limited
effect on simeprevir activity, the resistance barrier for
Q80K-carrying variants appears to be lower. This potentially
facilitates the emergence of additional mutations, resulting
in a higher treatment failure rate in Q80K patientscompared with patients without Q80K when treated with
simeprevir in combination with PR.41
Results of this study are consistent with those of previ-
ous studies of simeprevir in combination with PR in treat-
ment-experienced30 and treatment-naive patients.27,33,34
SVR24 rates of 75% and 83% have been reported for
boceprevir and telaprevir, respectively, in combination with
PegIFN/RBV in patients who relapsed after prior IFN-based
therapy.11,14 The SVR24 rates in the placebo control groups
in these studies were 24% and 29%, respectively. The
SVR24 rate was 69% in boceprevir-treated patients who
were HCV RNA negative at weeks 8 and 12 and therefore
eligible for a shorter overall duration of PegIFN/RBV (36
weeks).11 No data concerning the potential for RGT with
telaprevir in relapsed patients have been reported.
The safety and tolerability proﬁle of simeprevir/PR in
the present study was generally similar to that of PR
alone,42 with no additional treatment-related AEs reported.
The improved virologic response rates achieved by addition
of simeprevir to PR allowed a reduction in total treatment
duration for most patients, which signiﬁcantly reduced
exposure to PR and time with treatment-related side effects
overall for simeprevir-treated compared with placebo-
treated patients. AEs were generally mild and clinically
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no patient discontinued simeprevir because of AEs. No
increased incidence for simeprevir/PR compared with PR
alone was seen for rash, pruritus, neutropenia, or anemia
AEs, despite the fact that use of erythropoiesis-stimulating
agents was not allowed in this study. These events were
considered of clinical interest because an increased inci-
dence has been reported with boceprevir and
telaprevir.11–14,22 Mild and transient bilirubin increases
were seen in simeprevir-treated patients; however, no
concomitant increases in other laboratory liver parameters
were observed. This ﬁnding may be associated with inhi-
bition of bilirubin transporters OATP1B1 and MRP2 by
simeprevir,43 although RBV-induced hemolysis also may
cause bilirubin increases. The addition of simeprevir to PR
did not increase patient-reported fatigue, productivity
impairment, or activity impairment beyond what was
observed in patients who received PR alone, but did shorten
the duration of these treatment-related problems.
In conclusion, the addition of simeprevir 150 mg once
daily to PR substantially improved SVR rates in HCV geno-
type 1–infected patients who had relapsed after previous
IFN-based therapy, irrespective of IL28B genotype, META-
VIR score, HCV 1 subtype, or the presence of baseline
polymorphisms. The majority of simeprevir-treated patients
met RGT criteria, enabling a shorter, 24-week overall
duration of PR treatment. The addition of simeprevir to PR
generally was well tolerated, with safety and tolerability
similar to PR alone. Ongoing studies are investigating
simeprevir in both PegIFNa and IFN-free combinations,
including all oral regimens.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2014.02.051.References
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Supplementary Materials and Methods
Patients
Patients with the following deﬁned laboratory abnor-
malities were excluded from the trial: platelets less than
90,000/mm3, absolute neutrophil count less than 1500/
mm3, white blood cell count less than 3000/mL, hemoglobin
level less than 12 g/dL for women and less than 13 g/dL for
men, creatinine level greater than 1.5 mg/dL, alanine
aminotransferase and/or aspartate aminotransferase level
greater than 10 times the upper limit of laboratory normal
range, total serum bilirubin level 1.5 times or more the
upper limit of laboratory normal range, and a-fetoprotein
level greater than 50 ng/mL in subjects with cirrhosis
(METAVIR ﬁbrosis score, F4).
Assessments
Blood samples were collected at screening, on days 1, 3,
7, 14, and 28, at 4-week intervals thereafter until week 28,
at weeks 36, 42 and 48, and during follow-up evaluation
(weeks 52, 60, and 72).
Blood samples for biochemical and hematologic analyses
were obtained at screening and during scheduled visits,
when electrocardiogram, vital signs, and physical examina-
tion assessments also were performed.
Supplementary Results
Patients
Approximately 70% of patients were enrolled in Europe,
22% in North America, and 8% in Australia and
New Zealand. The majority of patients were male (65.6%),
94.4% were white, their median age was 52 years, and their
median body mass index was 27.0 kg/m2. A signiﬁcant
proportion of patients had bridging ﬁbrosis (METAVIR F3
[15.4%]) or cirrhosis (METAVIR F4 [15.2%]). All patients
were infected with HCV genotype 1 (41.7% with HCV ge-
notype 1a, and 58.0% with HCV genotype 1b). In terms of
IL28B genotype, 24.4% had CC, 63.6% had CT, and 12.0%
had TT. Most patients had received prior PegIFN-based
therapy (67.7% had received PegIFNa-2a/RBV and 27.0%
had received PegIFNa-2b/RBV). The median baseline
HCV-RNA level was 6.5 log10 IU/mL (range, 3.1–7.7 log10
IU/mL), with 83.7% of patients having baseline HCV-RNA
levels greater than 800,000 IU/mL. The Q80K poly-
morphism was present at baseline in 13.1% of patients
(12.1% [31 of 257] in the simeprevir/PR group and 15.0%
[20 of 133] in the placebo/PR group). Among the 51 pa-
tients with Q80K at baseline, only 1 was infected with HCV
genotype 1b (enrolled in the simeprevir arm). The preva-
lence of Q80K at baseline among patients infected with HCV
genotype 1a was 30.7% (50 of 163).
Efﬁcacy
At the time of this primary week 60 analysis, the
SVR24 assessment time point had been reached by 254 of
260 patients in the simeprevir/PR group and by 64 of
133 patients in the placebo/PR group. The SVR24 rate
was higher among simeprevir-treated patients (78.3%
[199 of 254] vs 31.3% [20 of 64]; adjusted difference,
47.1%; 95% CI, 34.8–59.5; P < .001). All simeprevir-
treated patients who achieved SVR24 had HCV-RNA
levels less than 25 IU/mL undetectable at the SVR24
time point.
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Supplementary Figure 1. Study design. Response-guided
treatment in simeprevir (SMV) arm: if HCV-RNA level was
less than 25 IU/mL at week 4 and undetectable at week 12,
complete treatment at week 24. Stopping rules: if HCV-RNA
level was greater than 1000 IU/mL at week 4, stop SMV/
placebo; if HCV-RNA level was less than 2 log10 IU/mL
reduction at week 12, or conﬁrmed 25 IU/mL or greater at
week 24 or 36, stop all treatment. PR, peginterferon a-2a 180
mg/week þ ribavirin 1000–1200 mg/day; QD, once daily;
SMV, simeprevir.
Supplementary
Figure 2.Patient disposition.
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Supplementary Table 1.Univariate Analyses of Baseline Characteristics, Pharmacokinetic Exposure Measures, and Early
Response Parameters on SVR12 in the Simeprevir/PR Treatment Arm (Intent-to-Treat Population)
P value (likelihood ratio test) Signiﬁcance levela
Age, y .455
Baseline ALT level, U/L (nonlinear) .731
BMI, kg/m2 (nonlinear) .002 **
Baseline HCV-RNA level, log10 IU/mL .080
Height, cm (nonlinear) .633
Weight, kg (nonlinear) .052
HCV genotype/subtype .002 **
Baseline Q80K <.001 ***
Sex .345
HCV genotype/subtype, baseline Q80K <.001 ***
IL28B .023 *
METAVIR score .299
Race .583
Region <.001 ***
AUC24h (log10 ng$h/mL) .070
Predose plasma concentration (log10 ng/mL) .081
cEVR <.001 ***
eRVR <.001 ***
RVR <.001 ***
HCV RNA <25 IU/mL at week 4 <.001 ***
NOTE. Generalized additive modeling methodology using cubic spline functions was applied in the analysis. Nonlinear
indicates that a cubic spline function with 2 degrees of freedom was used to model SVR12.
ALT, alanine transaminase; AUC, area under concentration-time curve; BMI, body mass index; cEVR, complete early virologic
response; eRVR, extended rapid virologic response.
aStatistical signiﬁcance level of likelihood ratio test: *<.05, **<.01, ***<.001.
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